



PATENT
CEDAR-44649

January 30, 2001


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rostyslav Stoika et al.
Serial No. 09/687,911
Filed: October 13, 2000
For: MODULATING ACTIVATION OF LYMPHOCYTES AND
SCREENING POTENTIAL IMMUNOMODULATING
AGENTS BY TARGETING PITUITARY TUMOR
TRANSFORMING GENE (PTTG) EXPRESSION AND/OR
FUNCTION
Examiner: Unknown
Unit: --

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT


Assistant Commissioner for Patents
Washington, D. C. 20231

Dear Sir:

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS	
WASHINGTON, D. C. 20231, ON	January 30, 2001 DATE
BY 	ANN WEISS
January 30, 2001 (DATE OF SIGNATURE)	

Applicant's attorney submits herewith copies of the patents and/or other literature of which he is aware, that he believes may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

Applicant's attorney further submits herewith Form PTO-1449, "Information Disclosure Statement" by Applicant. A copy of each of the disclosed patents and other references listed as other documents Nos. 1-31 are not being submitted herewith, because under Rule 37 C.F.R. § 1.98(d) this art was previously cited by the Examiner and/or the Applicant in connection with U.S. Serial No. 09/569,956, filed May 12, 2000. This previously filed Application was cited by applicant in this present Application per 35 U.S.C. §§ 120 and 119(e).



PATENT
CEDAR-44649

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists (37 C.F.R. 1.97(h)). Further the filing of this information disclosure statement shall not be construed as an admission against interest in any manner.

It is believed that this information disclosure statement is being filed before the mailing of a first office action on the merits.

The Commissioner is hereby authorized to credit overpayments or charge any fees required under 37 C.F.R. 1.16 or C.F.R. 1.17 to Deposit Account No. 501597.

Respectfully submitted,

By: 

Nisan A. Steinberg, Ph.D.
Registration No. 40,345

555 West Fifth Street
Los Angeles, California 90013-1010
Ofc: 213/ 896-6665
Fax: 213/896-6600